$HYPR News

Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness

Full Transcript: Hyperfine Q2 2026 Earnings Call

Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially

Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

Hyperfine Announces Peer-Reviewed Publication Of NEURO PMR Study In Journal Of Neuroimaging

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Hyperfine Receives FDA Clearance For Its Latest Optive AI Software Update; Plans Rollout Of New Software In The U.S. In September

Hyperfine (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine, Inc. 2026 Q2 - Results - Earnings Call Presentation

B. Riley Securities Reiterates Buy on Hyperfine, Lowers Price Target to $1.6

Hyperfine, Inc. Q2 2026 Earnings Call Summary